These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 29138980)

  • 21. Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma.
    Anichini A; Molla A; Vegetti C; Bersani I; Zappasodi R; Arienti F; Ravagnani F; Maurichi A; Patuzzo R; Santinami M; Pircher H; Di Nicola M; Mortarini R
    Cancer Res; 2010 Nov; 70(21):8378-87. PubMed ID: 20861189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro-generated MART-1-specific CD8 T cells display a broader T-cell receptor repertoire than ex vivo naïve and tumor-infiltrating lymphocytes.
    Benveniste PM; Nakatsugawa M; Nguyen L; Ohashi PS; Hirano N; Zúñiga-Pflücker JC
    Immunol Cell Biol; 2019 Apr; 97(4):427-434. PubMed ID: 30633397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation of gap junctions in melanoma and their impact on Melan-A/MART-1-specific CD8⁺ T lymphocyte emergence.
    Benlalam H; Carré T; Jalil A; Noman Z; Caillou B; Vielh P; Tittarelli A; Robert C; Chouaib S
    J Mol Med (Berl); 2013 Oct; 91(10):1207-20. PubMed ID: 23744108
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative TCR:pMHC Dissociation Rate Assessment by NTAmers Reveals Antimelanoma T Cell Repertoires Enriched for High Functional Competence.
    Gannon PO; Wieckowski S; Baumgaertner P; Hebeisen M; Allard M; Speiser DE; Rufer N
    J Immunol; 2015 Jul; 195(1):356-66. PubMed ID: 26002978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor antigen-specific T-cells are Present in the CD8alphaalpha+ T-cell effector-memory pool.
    Magalhaes I; Vudattu NK; Jäger E; Maeurer MJ
    J Immunother; 2008; 31(9):840-8. PubMed ID: 18833003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Umbilical cord blood T cells respond against the Melan-A/MART-1 tumor antigen and exhibit reduced alloreactivity as compared with adult blood-derived T cells.
    Merindol N; Grenier AJ; Caty M; Charrier E; Duval A; Duval M; Champagne MA; Soudeyns H
    J Immunol; 2010 Jul; 185(2):856-66. PubMed ID: 20543110
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro.
    Li Y; Liu S; Hernandez J; Vence L; Hwu P; Radvanyi L
    J Immunol; 2010 Jan; 184(1):452-65. PubMed ID: 19949105
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD8+ CD28- and CD8+ CD57+ T cells and their role in health and disease.
    Strioga M; Pasukoniene V; Characiejus D
    Immunology; 2011 Sep; 134(1):17-32. PubMed ID: 21711350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antigen specificity determines the pro- or antitumoral nature of CD8+ T cells.
    Cuff S; Dolton G; Matthews RJ; Gallimore A
    J Immunol; 2010 Jan; 184(2):607-14. PubMed ID: 20007540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy.
    Tjin EP; Konijnenberg D; Krebbers G; Mallo H; Drijfhout JW; Franken KL; van der Horst CM; Bos JD; Nieweg OE; Kroon BB; Haanen JB; Melief CJ; Vyth-Dreese FA; Luiten RM
    Clin Cancer Res; 2011 Sep; 17(17):5736-47. PubMed ID: 21750202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interrupting CD28 costimulation before antigen rechallenge affects CD8(+) T-cell expansion and effector functions during secondary response in mice.
    Fröhlich M; Gogishvili T; Langenhorst D; Lühder F; Hünig T
    Eur J Immunol; 2016 Jul; 46(7):1644-55. PubMed ID: 27122236
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer.
    Meng Q; Liu Z; Rangelova E; Poiret T; Ambati A; Rane L; Xie S; Verbeke C; Dodoo E; Del Chiaro M; Löhr M; Segersvärd R; Maeurer MJ
    J Immunother; 2016; 39(2):81-9. PubMed ID: 26849077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4.
    Klein O; Ebert LM; Nicholaou T; Browning J; Russell SE; Zuber M; Jackson HM; Dimopoulos N; Tan BS; Hoos A; Luescher IF; Davis ID; Chen W; Cebon J
    Clin Cancer Res; 2009 Apr; 15(7):2507-13. PubMed ID: 19318477
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simultaneous coexpression of memory-related and effector-related genes by individual human CD8 T cells depends on antigen specificity and differentiation.
    Gupta B; Iancu EM; Gannon PO; Wieckowski S; Baitsch L; Speiser DE; Rufer N
    J Immunother; 2012 Jul; 35(6):488-501. PubMed ID: 22735807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dominant human CD8 T cell clonotypes persist simultaneously as memory and effector cells in memory phase.
    Touvrey C; Derré L; Devevre E; Corthesy P; Romero P; Rufer N; Speiser DE
    J Immunol; 2009 Jun; 182(11):6718-26. PubMed ID: 19454666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients.
    Speiser DE; Schwarz K; Baumgaertner P; Manolova V; Devevre E; Sterry W; Walden P; Zippelius A; Conzett KB; Senti G; Voelter V; Cerottini JP; Guggisberg D; Willers J; Geldhof C; Romero P; Kündig T; Knuth A; Dummer R; Trefzer U; Bachmann MF
    J Immunother; 2010 Oct; 33(8):848-58. PubMed ID: 20842051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA.
    Liénard D; Rimoldi D; Marchand M; Dietrich PY; van Baren N; Geldhof C; Batard P; Guillaume P; Ayyoub M; Pittet MJ; Zippelius A; Fleischhauer K; Lejeune F; Cerottini JC; Romero P; Speiser DE
    Cancer Immun; 2004 May; 4():4. PubMed ID: 15149168
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TCRs genetically linked to CD28 and CD3ε do not mispair with endogenous TCR chains and mediate enhanced T cell persistence and anti-melanoma activity.
    Govers C; Sebestyén Z; Roszik J; van Brakel M; Berrevoets C; Szöőr Á; Panoutsopoulou K; Broertjes M; Van T; Vereb G; Szöllősi J; Debets R
    J Immunol; 2014 Nov; 193(10):5315-26. PubMed ID: 25320284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Altered ex vivo balance between CD28+ and CD28- cells within HIV-specific CD8+ T cells of HIV-seropositive patients.
    Dalod M; Sinet M; Deschemin JC; Fiorentino S; Venet A; Guillet JG
    Eur J Immunol; 1999 Jan; 29(1):38-44. PubMed ID: 9933084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients.
    Baitsch L; Baumgaertner P; Devêvre E; Raghav SK; Legat A; Barba L; Wieckowski S; Bouzourene H; Deplancke B; Romero P; Rufer N; Speiser DE
    J Clin Invest; 2011 Jun; 121(6):2350-60. PubMed ID: 21555851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.